[1]
|
Huang, D., Ding, Y., Li, Y., Luo, W.M., Zhang, Z.F., Snider, J., Vandenbeldt, K., Qian, C.N. and Teh, B.T. (2010) Sunitinib Acts Primarily on Tumor Endothelium Rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. Cancer Research, 70, 1053-1062. http://dx.doi.org/10.1158/0008-5472.CAN-09-3722
|
[2]
|
Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L.E., Bollag, G. and Trail, P.A. (2004) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Research, 64, 7099-7109.
http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
|
[3]
|
Lassau, N., Koscielny, S., Albiges, L., Chami, L., Benatsou, B., Chebil, M., Roche, A. and Escudier, B.J. (2010) Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography. Clinical Cancer Research, 16, 1216-1225.
|
[4]
|
Negrier, S. and Raymond, E. (2012) Antiangiogenic Treatments and Mechanisms of Action in Renal Cell Carcinoma. Investigational New Drugs, 30, 1791-1801. http://dx.doi.org/10.1007/s10637-011-9677-6
|
[5]
|
Garcia-Donas, J., Esteban, E., Leandro-Garcia, L.J., Castellano, D.E., del Alba, A.G., Climent, M.A., Arranz, J.A., Gallardo, E., Puente, J., Bellmunt, J., Mellado, B., Martinez, E., Moreno, F., Font, A., Robledo, M. and Rodriguez-Antona, C. (2011) Single Nucleotide Polymorphism Associations with Response and Toxic Effects in Patients with Advanced Renal-Cell Carcinoma Treated with First-Line Sunitinib: A Multicentre, Observational, Prospective Study. The Lancet Oncology, 12, 1143-1150. http://dx.doi.org/10.1016/S1470-2045(11)70266-2
|
[6]
|
Lee, Y.S., Kim, B.H., Kim, B.C., Shin, A., Kim, J.S., Hong, S.H., Hwang, J.A., Lee, J.A., Nam, S., Lee, S.H., Bhak, J. and Park, J.W. (2015) SLC15A2 Genomic Variation Is Associated with the Extraordinary Response of Sorafenib Treatment: Whole-Genome Analysis in Patients with Hepatocellular Carcinoma. Oncotarget, 6, 16449-16460.
http://dx.doi.org/10.18632/oncotarget.3758
|
[7]
|
Penel, N., Ray-Coquard, I., Bal-Mahieu, C., Chevreau, C., Le Cesne, A., Italiano, A., Bompas, E., Clisant, S., Baldeyrou, B., Lansiaux, A., Robin, Y.M., Bay, J.O., Piperno-Neumann, S., Blay, J.Y. and Fournier, C. (2014) Low Level of Baseline Circulating VEGF-A Is Associated with Better Outcome in Patients with Vascular Sarcomas Receiving Sorafenib: An Ancillary Study from a Phase II Trial. Targeted Oncology, 9, 273-277.
http://dx.doi.org/10.1007/s11523-013-0299-0
|
[8]
|
Garcia-Roig, M., Ortiz, N. and Lokeshwar, V. (2014) Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need? Current Urology Reports, 15, 375.
http://dx.doi.org/10.1007/s11934-013-0375-0
|
[9]
|
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A.J., Salm, M.P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C.R., Martinez, P., Phillimore, B., Begum, S., Rabinowitz, A., Spencer-Dene, B., Gulati, S., Bates, P.A., Stamp, G., Pickering, L., Gore, M., Nicol, D.L., Hazell, S., Futreal, P.A., Stewart, A. and Swanton, C. (2014) Genomic Architecture and Evolution of Clear Cell Renal Cell Carcinomas Defined by Multiregion Sequencing. Nature Genetics, 46, 225-233. http://dx.doi.org/10.1038/ng.2891
|
[10]
|
Bousquet, G., Bouchtaoui, M.E., Leboeuf, C., Battistella, M., Varna, M., Ferreira, I., Plassa, L.F., Hamdan, D., Bertheau, P., Feugeas, J.P., Damotte, D. and Janin, A. (2015) Tracking Sub-Clonal TP53 Mutated Tumor Cells in Human Metastatic Renal Cell Carcinoma. Oncotarget, 6, 19279-19289. http://dx.doi.org/10.18632/oncotarget.4220
|
[11]
|
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., Zreik, F., Porat, R.M., Finkelstein, R., Reuter, H., Koschny, R., Ganten, T., Mogler, C., Shibolet, O., Hess, J., Breuhahn, K., Grunewald, M., Schirmacher, P., Vogel, A., Terracciano, L., Angel, P., Ben-Neriah, Y. and Pikarsky, E. (2014) Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 4, 730-743. http://dx.doi.org/10.1158/2159-8290.cd-13-0782
|
[12]
|
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. http://dx.doi.org/10.1016/j.ejca.2008.10.026
|
[13]
|
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J. and Wittwer, C.T. (2009) The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clinical Chemistry, 55, 611-622.
http://dx.doi.org/10.1373/clinchem.2008.112797
|
[14]
|
Fukudo, M., Ito, T., Mizuno, T., Shinsako, K., Hatano, E., Uemoto, S., Kamba, T., Yamasaki, T., Ogawa, O., Seno, H., Chiba, T. and Matsubara, K. (2014) Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma. Clinical Pharmacokinetics, 53, 185-196.
http://dx.doi.org/10.1007/s40262-013-0108-z
|
[15]
|
Gooskens, S.L., Furtwangler, R., Spreafico, F., van Tinteren, H., de Kraker, J., Vujanic, G.M., Leuschner, I., Coulomb-L’Hermine, A., Godzinski, J., Schleiermacher, G., Stoneham, S., Bergeron, C., Pritchard-Jones, K., Graf, N. and van den Heuvel-Eibrink, M.M. (2014) Treatment and Outcome of Patients with Relapsed Clear Cell Sarcoma of the Kidney: A Combined SIOP and AIEOP Study. British Journal of Cancer, 111, 227-233.
http://dx.doi.org/10.1038/bjc.2014.291
|
[16]
|
Xiong, Y.Q., Sun, H.C., Zhang, W., Zhu, X.D., Zhuang, P.Y., Zhang, J.B., Wang, L., Wu, W.Z., Qin, L.X. and Tang, Z.Y. (2009) Human Hepatocellular Carcinoma Tumor-Derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 4838-4846.
http://dx.doi.org/10.1158/1078-0432.CCR-08-2780
|
[17]
|
Fiorio Pla, A., Brossa, A., Bernardini, M., Genova, T., Grolez, G., Villers, A., Leroy, X., Prevarskaya, N., Gkika, D. and Bussolati, B. (2014) Differential Sensitivity of Prostate Tumor Derived Endothelial Cells to Sorafenib and Sunitinib. BMC Cancer, 14, 939. http://dx.doi.org/10.1186/1471-2407-14-939
|
[18]
|
Paule, B., Bastien, L., Deslandes, E., Cussenot, O., Podgorniak, M.P., Allory, Y., Naimi, B., Porcher, R., de La Taille, A., Menashi, S., Calvo, F. and Mourah, S. (2010) Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas. PloS One, 5, e10715.
http://dx.doi.org/10.1371/journal.pone.0010715
|
[19]
|
Bousquet, G., Varna, M., Ferreira, I., Wang, L., Mongiat-Artus, P., Leboeuf, C., de Bazelaire, C., Faivre, S., Bertheau, P., Raymond, E., Germain, S. and Janin, A. (2013) Differential Regulation of Sunitinib Targets Predicts Its Tumor-Type-Specific Effect on Endothelial and/or Tumor Cell Apoptosis. Cancer Chemotherapy and Pharmacology, 72, 1183-1193. http://dx.doi.org/10.1007/s00280-013-2300-0
|